The EMPULSE trial showed the effects of empagliflozin on symptoms, physical limitations and quality of life in patients hospitalized for acute heart failure. touchCARDIO speaks with Prof. Mikhail Kosiborod (Saint Luke’s Mid America Heart Institute, Kansas City, MO) to discuss his presentation on the EMPULSE trial and the impact of SGLT-2 inhibitors and where they sit in the future treatment paradigm for heart failure.
- What has been the impact of SGLT-2 inhibitors on the treatment of heart failure, and what questions remain unanswered? (00:13)
- What were the aims, design, and inclusion criteria of the EMPULSE trial? (03:03)
- What were the efficacy and safety findings of the study? (04:27)
- What is the clinical significance of these findings? (07:17)
- What does the future hold for SGLT-2 inhibitors in the treatment of heart failure? (08:21)
Disclosures: Mikhail Kosiborod is a consultant for Alnylam, Amgen, Applied Therapeutics, Astra Zeneca, Bayer, Boehringer Ingelheim, Cytokinetics, Eli Lilly, Esperion Therapeutics, Janssen, Lexicon, Merck (Diabetes and Cardiovascular), Novo Nordisk, Pharmacosmos, Sanofi, Vifor Pharma.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Shanice Allen.
Filmed in coverage of the American College of Cardiology Annual Meeting 2022
Share this Video
Related Videos In Heart Failure
Divaka Perera, ESC 2022: Percutaneous revascularisation in patients with severe ischaemic cardiomyopathy, the REVIVED trial
The REVIVED study aimed to assess whether the addition of stents when treating patients with severe ischaemic cardiomyopathy would be beneficial to patient outcomes. In this touchCARDIO interview, we speak with Professor Divaka Perera (King’s College London, London, UK) to discuss the REVIVED trial, its outcomes and how they will affect the current treatment paradigm. […]
Divaka Perera, ESC 2022: The unmet needs in patients with heart failure due to ischaemic cardiomyopathy
In an ideal scenario, patients with ischaemic cardiomyopathy would receive specific treatment options beyond the general heart failure management currently in place. In this touchCARDIO interview, we speak with Professor Divaka Perera (King’s College London, London, UK) to discuss the unmet needs in this population and give an evaluation of surgical and percutaneous revascularization in […]
Caroline Sindet-Pedersen, ESC 2022: SARS-CoV-2 mRNA vaccines in patients with heart failure
Studies investigating the safety and efficacy of the severe acute respiratory syndrome coronavirus 2 infection (SARS-CoV-2) mRNA vaccines lacked representation of patients with heart failure. In this touchCARDIO interview, we speak with Dr Caroline Sindet-Pedersen (Copenhagen University Hospital Herlev and Gentofte, Hellerup, Denmark) to discuss the study presented at ESC 2022 that aimed to investigate […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!